Cofactor Genomics uses RNA to help researchers and clinicians understand, diagnose, and predict drug response for the 95% of disease that can’t be assessed by DNA alone.

Cofactor Genomics offers its full-service molecular, informatic, and database tools to make drug discovery, clinical trials and therapy selection more successful. Contacts: Tim Baker 919.969.3492 ...

Cofactor AI is leveling the playing field in the AI arms race between payers and providersCHICAGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Hospitals across the country are facing an ever-increasing ...

Cofactor is supported and partnered with 38 healthcare systems, representing 20% of US healthcare. Cofactor’s OncoPrism is CAP/CLIA-validated and Medicare-approved.

Cofactor Genomics has announced an $18 million Series A financing round led by Menlo Ventures, with participation from DCVC, Ascension Ventures, iSelect, Y Combinator, Wilson Sonsini Goodrich ...

Cofactor Genomics has acquired Narus Biotechnologies, for an undisclosed price, in a deal designed to advance the buyer’s expansion into RNA-based diagnostics Cofactor said the acquisition will ...

It’s the first artificial cofactor that’s efficient enough to do that, Li says. “Central carbon metabolism is like the highway of metabolism, so it’s got the highest flux.

Cofactor Genomics, a biotech company operating out of the Cortex innovation district, has made its first acquisition since being founded in St. Louis in 2008.

While Cofactor focuses on RNA, there is a whole wave of DNA diagnostic companies that have been funded in Silicon Valley in recent years, including Color Genomics, which tests for breast cancer ...

Oral challenges confirmed cofactor-dependent wheat allergies, restored quality of life and reduced fear of future reactions, according to a study published in Annals of Allergy, Asthma ...